Login / Signup

Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).

Bruce E StroberAndrew BlauveltRichard B WarrenKim A PappApril W ArmstrongKenneth B GordonAkimichi MoritaAndrew F AlexisMark LebwohlPeter FoleyRenata M KisaElizabeth ColstonTao WangSubhashis BanerjeeDiamant Thaçi
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Deucravacitinib was well-tolerated with acceptable safety over 52 weeks in patients with psoriasis.
Keyphrases
  • gestational age
  • coronary artery disease
  • open label
  • early onset
  • high intensity
  • atopic dermatitis
  • randomized controlled trial
  • clinical trial
  • phase iii